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Abstract The rabbit ¢tsl-casein gene contains a distal prolac- 
tin-dependent enhancer 3442-3285 bp 5' to the site of initiation 
of transcription. We have reported previously that four DNAI 
protein-binding sites (F1-F4) are located within this distal 
enhancer. We now show that one of this binding site (the F4 
site) binds in vitro a MGFISTAT5-1ike factor. The functional 
importance of the F4 site was estimated by cotransfection of 
CHO cells with a chimeric gene containing or not the F4 
sequence linked to the (-3911+1774)CA T gene and a plasmid 
encoding the rabbit mammary prolactin receptor. The F4 site is 
necessary for maximal response of the enhancer to prolactin. 
However, this site has to be associated to the F1-F3 fragment. It 
can be replaced by a genuine MGF/STAT5-binding site. A 
mutational analysis indicates that F4 and F1 sites are 
simultaneously involved to confer a high prolactin sensitivity. 
Key words: Mammary gland; Primary cell; MGF/STAT5; 
¢xsl-casein; Milk protein gene expression; Electrophoretic 
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nuclear factor to the corresponding proximal binding site is 
necessary for prolactin sensitivity of the milk protein gene 
promoter. 
Despite the fundamental importance of the proximal pro- 
moter in the regulation of milk protein gene transcription, it 
has been reported that the presence of more upstream regu- 
latory gene elements i essential for high transcription levels in 
several genes. This was described in the bovine ~-casein gene 
[10], in the rabbit c~sl-casein gene [11] and in the rabbit [12] or 
rat whey acidic protein (WAP)  gene [13]. We have previously 
identified four rabbit mammary gland nuclear factor-binding 
regions within the distal regulatory -3442/ -3285 fragment in 
the rabbit e~sl-casein gene [8]. In the present study, we provide 
evidence that one of these binding sites (F4 ( -3333/-3307) 
site) is a genuine MGF/STAT5-binding site and that binding 
of a MGF/STAT5-1ike nuclear factor to the F4 site is neces- 
sary for the maximal enhancer activity of the distal regulatory 
element. 
1. Introduction 2. Materials and methods 
Milk protein gene expression is regulated in the mammary 
gland by various factors, involving hormones (mainly prolac- 
tin and glucocorticoids) and the extracellular matrix. Several 
gene-regulatory elements involved in the regulation of milk 
gene transcription have already been identified and a charac- 
terization of the nuclear factors bound to these elements has 
been attempted in some cases. Among these factors, the mam- 
mary gland factor (MGF) has been characterized [1], purified 
[2] and cloned in sheep [3], mice [4,5], rats [6] and humans [7]. 
This factor belongs to the multigene family of signal transdu- 
cers and activators of transcription (STAT family), and was 
renamed STAT5. The MGF/STAT5 factor is clearly involved 
in the prolactin activation of several milk protein gene tran- 
scription in various species. A functional MGF/STAT5-bind- 
ing site has been identified in the proximal promoters in the 
rat ~-casein gene [1], in the rabbit cxsl-casein gene [8], in the 13- 
lactoglobulin gene [9]. In these studies, it was demonstrated 
that the binding of MGF/STAT5 or of a MGF/STAT5-1ike 
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2.1. Cell culture and transient expression procedure 
CHO K1 cells were grown and transfected as previously described 
[14] with modifications [11]. Transfection of plasmid DNA was per- 
formed using the calcium phosphate procedure, with 40 gg DNA in 
each precipitate. Each precipitate was obtained with 6 gg of the CAT 
plasmid to be tested, 12 gg of the pCHll0 plasmid coding for 13- 
galactosidase (Pharmacia), 12 gg of the plasmid pER2-3 carrying 
the rabbit mammary prolactin receptor cDNA [15], and 10 gg of 
carrier DNA (genomic sonicated DNA from salmon testes). After 
~5-h incubation in the presence of the precipitate, the cells were 
washed and cultured in serum-free medium [14] containing hormones. 
Two dishes were incubated with cortisol (60 nM). Cortisol and ovine 
prolactin (16 nM; NIH, Bethesda, MD) were added to two other 
dishes. Cells were harvested 72 h later. CAT assays were performed 
as previously described [11]. CAT values were normalized to 13-galac- 
tosidase activity [16]. The prolactin fold inductions were calculated as 
the ratio of normalized CAT/[3-galactosidase activity in prolactin- 
plus cortisol-treated cells versus cortisol-treated cells. 
2.2. Rabbit primary mammary cell culture 
Organoids were isolated from the mammary gland of one 18-day 
pregnant rabbit by limited collagenase (200 U/ml) and hyaluronidase 
(200 U/ml) digestion for 90 min as previously described [12]. They 
were seeded on plastic dishes in DMEM-Ham's F12 medium (1 : 1) 
supplemented with 2% UltroSer SF (Biosepra, France) as serum sub- 
stitute devoided of steroids and prolactin. Organoids prepared from 
one mammary gland were seeded on 40 dishes (10 cm diameter) then 
treated 4 days later for 10 min by insulin (5 gg/ml) or by insulin (5 gg/ 
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ml) plus ovine prolactin (1 p~g/ml). The dishes were then rapidly frozen 
on dry ice and kept at -80°C until preparation of nuclear extracts. 
2.3. Preparation of nuclear extracts 
Nuclear extracts were prepared from lactating mammary glands or 
from cultured mammary cells. The mammary tissue was rapidly dis- 
sected to eliminate most of the connective and muscular tissue, then 
frozen in liquid nitrogen and stored at -80°C. 
Nuclei were prepared from frozen mammary tissue as described [17] 
with modifications. Two buffers (A: 10 mM HEPES (pH 7.7), 50 mM 
KCI, 2 mM EDTA, 10% glycerol, 0.25 M sucrose; B: similar to A 
with 0.9 M instead of 0.25 M sucrose) were prepared and kept at 4°C. 
Extemporaneously, dithiothreitol (0.5 mM DTT), spermine (0.15 
mM), spermidine (0.5 mM), protease inhibitor (0.5 mM phenyl- 
methylsulfonyl fluoride (PMSF)) and phosphatase inhibitors (1 mM 
sodium fluoride, 1 mM sodium vanadate and 10 I.tM ammonium 
molibdate) were added to these buffers. All steps were carried out 
at 4°C. Frozen tissue was pulverized in liquid nitrogen. Buffer A 
(10 vol/g of frozen tissue) was added onto the frozen powder. The 
mixture was then homogenized by 4~8 strokes in a motor-driven glass/ 
teflon Potter. The homogenate was filtered on 5 layers of gauze. The 
resulting homogenate was layered on a 0.9 M sucrose cushion (buffer 
B). Nuclei were pelleted by centrifugation for 10 min at 3500 rpm. 
Nuclei were prepared from frozen cells as follows. Frozen scraped 
primary cells from 10 dishes were pooled and thawed at 4°C in buffer 
1 (10 mM HEPES, pH 7.7, 25 mM KC1, 2 mM EDTA, 0.5 mM 
EGTA, 0.6 M sucrose, 0.8% NP40, with the same protease and phos- 
phatase inhibitors as previously indicated for mammary gland nuclei 
preparation) in order to attain a final 10-15 ml volume. After Dounce 
homogenization (10-15 strokes), the mixture was layered on 10 ml of 
buffer 2 (same as buffer 1 but with 1 M sucrose and without NP40). 
The nuclei were pelleted by centrifugation for 10 min at 3500 rpm. 
Nuclear extracts were prepared essentially as described [18] with 
modifications as previously reported [8]. 
2.4. Partial purification of rabbit mammary gland MGF/STAT5-like 
factor by oligonucleotide affinity 
Three millilitres of nuclear extract from lactating mammary gland 
were incubated overnight at 4°C with 500 ~tl of streptavidine agarose 
coupled with a biotinylated double-stranded W oligonucleotide (Gen- 
set, France) the sequence of which matches the -104/-85 position of 
the rabbit xsl-casein gene. As presented in Fig. 1, the sequence of the 
W oligonucleotide is homologous to the sequence of the consensus for 
the MGF/STAT5-binding site [8]. The agarose was then washed by 20 
ml of buffer D (20 mM Hepes, pH 7.7, 100 mM KC1, 0.2 mM EDTA, 
2% glycerol) containing protease inhibitors and sonicated salmon 
sperm DNA (200 I.tg/ml) as non-specific ompetitor. The specific 
bound factors were eluted twice with 500 Ixl of buffer D containing 
500 mM KC1. 
2.5. Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) was performed as pre- 
viously described [8]. Briefly, nuclear extracts were incubated at room 
temperature for 30 min with 0.5 p.g of poly dI~lC/poly (dI~dC, Phar- 
macia) as non-specific ompetitor in the reaction mixture with the 
following final salt concentrations: 20 mM Tris-HC1, pH 7.6, 80 
mM KC1, 8% Ficoll, 6% glycerol, 0.2 mM EDTA, 0.5 mM DTT. 
In competition experiments, a 100-fold molar excess of probe compet- 
itor was added. The sequences of the competitor oligonucleotides are 
given in Fig. 1. In supershift experiments, 1 ktl of rabbit immune 
serum directed against rabbit MGF/STAT5-1ike factor [19] or anti- 
phosphotyrosine antibody (Upstate Biotechnology, NY) was added 
with the nuclear extract to the binding buffer. After addition of 
30 000 cpm (30 pg) of a 5'-labelled ouble-stranded probe, incubation 
was performed at room temperature. After electrophoresis on a 6% 
acrylamide/bis-acrylamide non-denaturing gel in 0.25 × TBE buffer, 
the gel was transferred on DE81 paper, dried and exposed for auto- 
radiography. 
2.6. Plasmid constructions 
The plasmid pac(-391/+1774)CAT [8]consisted of 391 bp of the 
5'-flanking region of the rabbit o~sl-casein gene, the first non-coding 
exon (49 nt), the first intron (1719 nt), 5 nt of the second exon (not 
including the initiation site of the translation), the coding region of 
the CAT gene (including the initiation site of translation), and the 
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Fig. 1. Sequence of the oligonucleotides u ed in EMSA experiments. 
Sequences of the sense strands are given with the consensus e- 
quence previously established for binding of the MGF/STAT5 fac- 
tor [1]. Box and bold letters indicate the highly homologous region. 
The positions of the F1, F2, F3 and F4 protected areas in the distal 
regulatory element (-34421-3307) are indicated [8]. In M and Flm 
oligonucleotides, mutated nucleotides are indicated in light letters. 
polyadenylation signal of Simian virus-40 early genes cloned in the 
pPolyllI vector [20]. 
A -3442/-3333 fragment of rabbit xsl-casein gene was synthesized 
by polymerase chain reaction (PCR) using R1 (5'-TGTGAACT- 
GTCTCAGGTTCC-Y) and C (5'-CTTTCTATTACATAATGAA- 
TA-3') (complementary to the F3 oligonucleotide, see Fig. 1) as pri- 
mers and pac(-3772/+1774)CAT [8]as template. This fragment was 
subcloned in the EcoRV site in pBluescript KSII+ (Stratagene) to 
generate the S plasmid. Oligonucleotides F4, W or M presented in 
Fig. 1 were introduced in the EcoRI site of the S plasmid after blunt- 
ing by Klenow polymerase. The new generated plasmids were named 
S-F4, S-W or S-M. The S and S-F4 plasmids were digested by EcoRI 
and HindlII, the S-M and S-W plasmids were digested by HindlII 
and PstI. The inserts were purified by gel electrophoresis, blunt-ended 
by Klenow polymerase or T4 DNA polymerase, then subcloned in the 
BgllI site of pac(-391/+1774)CAT located at the 5'-border of the 
(xsl-casein gene fragment. 
A double mutation was created in the F1 region by site-directed 
mutagenesis by PCR using two complementary oligonucleotides F lm 
(5'-CTTCCACATTTGTCACTAAGTTTCCT-3') and Am (5'-AG- 
GAAACTTAGTGACAAATGTGGAAG-3') whose sequences are 
homologous to the sequence -3393/-3368 of the rabbit txsl-casein 
gene with one G instead of one C at position -3382 and one C 
instead of one G at position -3378. The mutated -3442/-3118 frag- 
ment was subcloned in the BamH1 site of the polylinker in pB1CAT2 
[21]. The mutated -3442/-3333 fragment was obtained by PCR using 
R1 and C as primers and, as template, the pBLCAT2 containing the 
mutated -3442/-4118 fragment. The -3442/-3333 fragment was 
then subcloned in the EcoRV site of pBluescript KSII+ to generate 
the M plasmid. The F4 double-strand oligonucleotide was inserted in 
the EcoRI site of the M plasmid after blunting by Klenow polymer- 
ase. The generated plasmid F4~M was digested by EcoRI and Hin- 
dlII. The insert was purified by gel electrophoresis, blunt-ended by 
Klenow polymerase then subcloned in the BgllI site of pac(-391/ 
+ 1774)CAT. 
3. Results 
3.1. The F4 ( -3333/ -3307)  fragment and MGF/STAT5-  
binding sequence W ( -104/ -85)  in the proximalpromoter 
of  the rabbit o~sl-casein gene bind in vitro similar nuclear 
factors 
The sequence of the F4-binding site in the distal enhancer 
presents several homologies with the MGF/STAT5-b ind ing 
consensus and with the W sequence (Fig. 1). We have pre- 
viously supposed that the W sequence could bind a rabbit  
mammary  gland MGF/STAT5-1ike nuclear factor [8]. In a 
first attempt to identify the nuclear factors which bind to 
the F4 site, we compared the properties of F4- and W-bound 
complexes in EMSA. Nuclear extracts prepared from lactating 
rabbit  mammary  glands or from primary mammary  cells were 
used. Competit ions were carried out with various oligonucleo- 
G. Jolivet et al./FEBS Letters 389 (1996) 257-262 259 
Mammary gland nuclear extract 
W probe F4 probe 







Fig. 2. Binding of nuclear factor to F4 (-3333/-3307) and W (-104/-85) probes. EMSA using mammary gland nuclear extracts was per- 
formed with 2.4 gg of proteins in each point with W (lanes 1-5) or F4 (lanes 6-12) as probe. Three microlitres of the affinity column eluted 
fraction containing partially purified MGF/STAT5-1ike nuclear factor (mixed with 8 gg of serum bovine albumin in each point) were used in 
EMSA with F4 as probe (lanes 13-17). The name of each competitor oligonucleotide (100x molar excess of non-labelled ouble-stranded oli-
gonucleotide) is indicated on top of each lane. The arrow indicates the position of the specific omplex. The length of exposure was adapted in 
each experiment to obtain approximatively similar signals for the specific bands on the autoradiographs. 
tides, including F1, F2 and F3, the sequences of which corre- 
spond to mammary gland nuclear factor-binding regions with- 
in the distal element. 
After incubating nuclear extracts from lactating mammary 
gland with a F4 probe, a retarded complex with a low migrat- 
ing rate was detected in EMSA (Fig. 2, lane 6). F4 and W 
oligonucleotides were efficient competitors (lanes 7 and 8). M 
oligonucleotide (which differs from W by two point muta- 
tions) and F1 oligonucleotide were poor competitors (lanes 
9 and I0). The heterologous oligonucleotides F2 and F3 had 
no effect (lanes 11 and 12). Several other complexes with high- 
er migrating rates were visible at the bottom of the gel; they 
were greatly reduced after addition of various oligonucleo- 
tides, except F3. The nature of these complexes remains un- 
clear and was not studied. 
When a partially purified MGF/STAT5-1ike nuclear factor 
was incubated with F4 as probe, one retarded complex was 
observed (lane 13). This complex comigrated with that ob- 
served with mammary gland nuclear extracts (compare lanes 
6 and 13). F4 or W oligonucleotides were efficient competi- 
tors. The addition of M oligonucleotide did not modify the 
binding (lanes 15-17). 
As expected, one retarded complex was observed after in- 
cubation of W as probe with nuclear extracts from lactating 
mammary gland (lane 1). A complete competition was ob- 
served in the presence of W and F4 oligonucleotides. F1 
was a poor competitor. These observations led us to conclude 
that the F4- and W-bound factors have identical electro- 
phoretic migration rates and DNA-binding specificity. 
To further characterize the nature of F4-bound factors, we 
used the MGF/STAT5-specific antiserum [19]. The F4-bound 
complex was shifted after addition of the immune serum (Fig. 
3, lane 2), indicating that the F4-bound complex and the 
MGF/STAT5 factor are immunologically related. Moreover, 
the complex diminished after addition of an antiphosphotyr- 
osine antibody (lane 3), indicating that the bound component 
is probably tyrosine phosphorylated, as previously described 
for the rat [22] or rabbit [19] MGF/STAT5 factor. In conclu- 
sion, the similarities between the DNA-binding specificity of 
F4- and W-bound factors as well as the result of the immu- 
nological characterization indicate therefore that the F4 frag- 
ment binds in vitro a MGF/STAT5-1ike factor. 
3.2. The binding of a MGF/STAT5-like factor to F4 is 
inducible by prolactin in cultured mammary gland cells 
Nuclear extracts from cultured rabbit mammary cells were 
incubated with F4 as probe and analysed in EMSA. A low 
migration rate retarded complex was observed only after pro- 
lactin treatment of the cells (Fig. 4, lanes 2-3). F4 or W 
oligonucleotides were efficient competitors (lanes 5 and 6), 
as it was observed for a lactating mammary gland nuclear 
extract or the partially purified MGF/STAT5-1ike nuclear fac- 
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Fig. 3. Immunological identification of the complex formed with the 
F4 sequence and mammary gland nuclear extract. EMSA was per- 
formed with F4 as probe and 2.4 lag of nuclear proteins extracted 
from a lactating mammary gland. The incubation was performed 
after addition of 1 ~tl of the rabbit immune serum directed against 
rabbit MGF/STAT5-1ike factor (lane 2) or 1 lam of antiphosphotyr- 
osine antibody (lane 3). The arrow indicates the position of the spe- 
cific complex. 
factor by Pierre et al. [8]), the sensitivity of the construct 
towards prolactin dropped (2.1-fold induction, lane 5). It 
was concluded that the presence of a F4-binding site is neces- 
sary to confer a high prolactin sensitivity to the (-391/ 
+1774)CAT gene. 
The F4 sequence was by itself not sufficient o induce a high 
prolactin sensitivity to the (-391/+1774)CAT gene (2.3-fold 
induction, lane 6). Other gene elements contained in the 
-3442/-3333 fragment are also necessary. We have pre- 
viously identified three binding sites in this area named F1, 
F2 and F3 [8]. Until now, the nature of the factors which bind 
to these sites remains unknown. In this study, we have inves- 
tigated the possible interactions between F4- and Fl-binding 
sites. The sequence of the F1 site presents everal homologies 
with the consensus equence for the binding of the MGF/ 
STAT5 factor (Fig. 1). Therefore, we have introduced a dou- 
ble mutation in this site, interverting G and C at positions 
-3382 and -3378. When the F4 sequence was linked to the 
-3442/-3333 fragment encompassing a F1 mutated frag- 
ment, the sensitivity towards prolactin was not different 
from that of the minimal construct (-391/+1774)CAT (1.9- 
tor (Fig. 2). Unexpectedly, the F1 oligonucleotide was a more 
efficient competitor for the F4-binding in mammary cell (Fig. 
4, lane 7) than in lactating mammary gland extract (Fig. 2, 
lane 10). Other complexes howing higher migration rates 
were observed. They were not affected by the addition of 
any of the oligonucleotides weemployed and, for this reason, 
they were considered as non-specific. The specific complex was 
shifted by addition of the rabbit MGF/STAT5-specific anti- 
serum (lane 4). This observation argues in favour of the idea 
that (1) the F4-bound factor is similar to MGF/STAT5, and 
(2) the binding of this factor to the F4 sequence is induced by 
prolactin in cultured mammary gland cells. 
1 
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3.3. The F4 sequence is necessary for maximal activity of the 
distal prolactin-dependent e hancer in the rabbit 
ty~sl-casein gene 
To assess the functional importance of the F4-binding site, 
CHO cells were cotransfected with gene constructs containing 
(or not) the F4 sequence linked to the (-391/+1774)CAT gene 
and with the plasmid pER2-3 which encodes the rabbit mam- 
mary prolactin receptor. Whatever the transfected CAT gene 
construct, he basal level of CAT activity determined in non- 
prolactin-treated cells was similar (data not shown). After 
prolactin treatment of the transfected cells, the CAT activity 
was elevated only twice when the (-391/+1774)CAT gene was 
transfected (Fig. 5, lane 1). When the -3442/-3333 fragment 
was linked upstream of the (-391/+1774)CAT gene, the pro- 
lactin sensitivity remained unchanged (lane 2). The prolactin 
sensitivity of the (-391/+1774)CAT gene was quite signifi- 
cantly enhanced when the -3442/-3307 gene fragment, which 
contains the F4 sequence, was linked upstream of the reporter 
construct (5.7-fold induction, lane 3). When the F4 sequence 
was replaced by the W sequence (the sequence of the proximal 
binding site of a MGF/STAT5-1ike factor in the rabbit ctsl- 
casein promoter), the prolactin sensitivity of the construct was 
high and not significantly different o that of the wild-type 
construct (7.5-fold induction, lane 4). After substitution of 
the F4 sequence by a mutated MGF/STAT5-binding sequence 
(M, previously described as unable to bind a MGF/STAT-like 
Fig. 4. Prolactin induction of the F4-bound complex in nuclear ex- 
tracts from cultured mammary gland cells. Rabbit primary mam- 
mary cells were maintained in culture medium for 4 days then treat- 
ed for 10 min with insuline (I, 5 lag/ml) or with insuline plus ovine 
prolactin (I+P, 1 lag/ml). Nuclear extracts were prepared and EMSA 
was performed with F4 as probe and 4-5 lag of nuclear protein in 
each point. The arrow indicates the location of the specific om- 
plexes. L, nuclear extracts from lactating mammary gland; ab, 
EMSA with MGF/STAT5-specific antiserum. 
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Fig. 5. The F4 sequence is necessary for maximal activity of the distal prolactin-dependent hancer in the rabbit ~sl-casein gene. Plasmids 
containing (or not) the F4 sequence were transfected into CHO cells with the plasmid pER2-3 expressing the rabbit mammary prolactin recep- 
tor. Transfected cells were treated for 72 h by cortisol or cortisol + prolactin (Prl) as described in Section 2. Prl induction was calculated as 
the ratio of CAT activity in Prl + cortisol-treated cells versus cortisol-treated cells. For each construct, at least wo different DNA preparations 
were used in three independent experiments. Values are means+SEM. 
fold induction, lane 7), indicating that the mutated istal frag- 
ment has no prolactin-dependent hancer activity. Thus, the 
F4- and Fl-binding sites interact simultaneously to confer a 
high prolactin sensitivity to the transfected gene construct. 
4. D iscuss ion  
In our previous work [8], we observed that the -3442/ 
-3285 fragment of the rabbit cxsl-casein gene was sufficient 
to confer a high prolactin sensitivity to the (-391/+1774)CAT 
construct. A nuclear factor-DNA binding study led us to lo- 
calize four proteirdDNA-binding areas in this fragment, which 
were named F1-F4 (Fig. 1). The sequence of the binding area 
F4 is highly homologous to the sequence of the binding site of 
the already identified MGF/STAT5 factor (Fig. 1). It was 
therefore postulated that the F4 site could bind a factor simi- 
lar to the MGF/STAT5 factor. The aim of the present study 
was to compare the F4-bound factor and a MGF/STAT5-1ike 
factor. 
Two types of experiments were carried out: first, an in vitro 
protein-binding DNA study and, secondly, a functional study. 
The specificity of the binding of nuclear factors to the F4 and 
W oligonucleotides were similar (W contains the proximal 
MGF/STAT5-binding site in the rabbit asl-casein promoter). 
The binding of the nuclear factor to the F4 sequence was 
prolactin inducible in cultured rabbit mammary cells, as it 
has been already described for the binding of rabbit primary 
mammary cells nuclear factor to a MGF/STAT5 sequence 
[19]. The migration rate of the F4 complex was modified by 
the addition of an antiserum directed against MGF/STAT5. 
All these data are strongly in favour of the idea that the F4 
sequence binds in vitro a MGF/STAT5-1ike factor. Data ob- 
tained by the functional study confirmed this hypothesis. The 
F4 sequence can be replaced by a W sequence (but not by a 
mutated W sequence) in the transfected constructs without 
any significant modification of the prolactin sensitivity of 
the chimeric gene. We thus suggest hat the F4 and W frag- 
ments bind in vivo similar nuclear factors, i.E., a MGF/ 
STAT5-1ike factor. 
Interestingly, the F4-bound complex appears wider in 
EMSA with cellular extracts compared to lactating mammary 
gland extracts (Fig. 4, lanes 1 and 3). This may be explained 
by the fact that the F4-bound complex is composed of several 
components in cell extracts. Following the results of the pres- 
ent study, one of this component is a MGF/STAT5-1ike fac- 
tor. The nature of the other components remains unknown. It 
is possible that another form of the MGF/STAT5-1ike factor 
binds to the same F4 probe. Several forms of MGF/STAT5 
have been identified in the mouse [4,5], in the early myeloid 
cell line FDC-P1 [23], in rats [6] or in humans [7]. Another 
explanation could be that the MGF/STAT5-1ike factor binds 
to the F4 probe in association with a second transcription 
factor, the nature of which is not elucidated. All these hypoth- 
eses have to be tested. 
A distal MGF/STAT5-binding site has already been identi- 
fied in the rat WAP gene [24]. According to the authors, the 
presence of this distal binding site is necessary to support a 
high expression of the gene in transgenic animals. The muta- 
tion of the distal MGF/STAT5-binding site considerably di- 
minished the level of expression of the transgene in mice with- 
out altering the tissue specificity. The presence of two NF1- 
binding sites was necessary as well. The authors concluded 
that the distal enhancer was composed of several interacting 
elements. 
Similarly to the rat WAP gene, the high level of prolactin- 
induced expression of the rabbit ~sl-easein gene depends on 
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the presence of a distal enhancer encompassing one MGF/  
STAT5-binding site. The F4-binding site alone is not sufficient 
to confer a high prolactin sensitivity to the chimeric o~sl-case- 
in gene-CAT gene. The 3' portion of the distal fragment en- 
compassing the F2, F1 and F3 sites is quite necessary. In a 
first attempt, we have demonstrated that the F4- and F1- 
binding sites interacted. The F1 sequence is homologous to 
the sequence of the MGF/STAT5-binding site (Fig. 1). In a 
preliminary study, we have observed several complexes in 
EMSA performed with F1 as probe and rabbit lactating mam- 
mary gland nuclear extract (unpublished ata). One of these 
complexes had binding characteristics similar to that of a 
MFG/STAT5-DNA complex and was inducible by prolactin 
in cultured mammary gland cells. It is thus possible that this 
F1 sequence also binds a MGF/STAT5-1ike factor. This hy- 
pothesis is now currently being studied. 
In our previous tudy, we demonstrated that the presence of 
a proximal MGF/STAT5-binding site was necessary for the 
enhancer activity of the distal fragment [8]. Our data indicate 
that the high prolactin sensitivity of the rabbit c~sl-casein gene 
depends on the interaction of multiple MGF/STAT5-binding 
sites, located in the proximal promoter and in the distal en- 
hancer. The F2- and F3-binding sites could also play an im- 
portant role. Their involvement in the high-level prolactin- 
dependent enhancer activity of the distal enhancer is under 
study. 
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